Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Wake Forest University Health Sciences
University of Wisconsin, Madison
Eli Lilly and Company
Verastem, Inc.
Eli Lilly and Company
Eli Lilly and Company
Pliant Therapeutics, Inc.
Eli Lilly and Company
Pfizer
Compass Therapeutics
TuHURA Biosciences, Inc.
Eli Lilly and Company
M.D. Anderson Cancer Center
BioNTech SE
Astellas Pharma Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ascendis Pharma A/S
Eikon Therapeutics
Rutgers, The State University of New Jersey
ModernaTX, Inc.
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca
M.D. Anderson Cancer Center
Erasca, Inc.
Novartis
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Mayo Clinic
Shenzhen Ionova Life Sciences Co., Ltd.
GI Innovation, Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
Merck Sharp & Dohme LLC
Imugene Limited
Novartis
Ascendis Pharma A/S
Tizona Therapeutics, Inc
Essen Biotech
University of California, San Diego
University of Iowa
Werewolf Therapeutics, Inc.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Prelude Therapeutics
University of Oklahoma
M.D. Anderson Cancer Center
Royal Marsden NHS Foundation Trust
University of California, San Diego
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC